Skip to main content
Metabolic SyndromeExercise and fitnessPeptides and GLP-1DrugPhase 4

What this study is

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume, improves vascular function of the conduit vessels, and enhances insulin's metabolic action in humans with Metabolic Syndrome. Subjects will be randomized to one of the 4 groups: control, exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 24 weeks of intervention.

What's being tested

  • Liraglutide

    Intervention · DRUG

    24 weeks of Liraglutide

  • Exercise training

    Intervention · OTHER

    24 weeks of Exercise training

  • Liraglutide + Exercise training

    Intervention · DRUG

    24 weeks of Liraglutide + Exercise training

Study details

Sponsor
University of Virginia
Conditions
Metabolic Syndrome
Enrolling
80 people
Starts
2020-11-01
Est. completion
2027-04-30
Design
Open-label, randomized, factorial, Phase 4
Record
View on ClinicalTrials.gov ↗